Small-cell lung cancer transformation approximately four years after surgery and adjuvant therapy for EGFR-mutant lung adenocarcinoma: a case report

Background Transformation of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) is a recognized mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and is associated with poor clinical outcomes. The optimal treatment strategy for transformed SCLC remains uncertain. Case presentation We report a case of EGFR exon 21 mutant lung adenocarcinoma in a 48-year-old woman who developed SCLC transformation approximately 4 years after surgery and postoperative adjuvant therapy. Clinical course and treatment Following the identification of SCLC, the patient received multiple treatment regimens, including platinum–etoposide chemotherapy, osimertinib, and local radiotherapy. A subsequent biopsy in 2019 again demonstrated small cell carcinoma. Peripheral blood molecular testing identified EGFR L858R, TP53 p.C242F, and RB1 c.607 + 1G > A-alterations. The patient died of respiratory failure in January 2020, approximately 6 years after the initial diagnosis and 20 months after the identification of SCLC transformation. Conclusion This case illustrates the clinical challenges of SCLC transformation in EGFR-mutant lung adenocarcinoma after a prolonged postoperative interval. The longitudinal treatment course and molecular findings provide additional clinical observations relevant to the management of transformed SCLC, although the contribution of individual treatments cannot be determined from a single case.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-12
DOI
https://doi.org/10.3389/fmed.2026.1982251
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Small-cell lung cancer transformation approximately four years after surgery and adjuvant therapy for EGFR-mutant lung adenocarcinoma: a case report

Hong Wang, Boyu Qin, Jing Zhao, Hao Zhang et al.
Frontiers in Medicine
Lung Cancer Treatments and Mutations
article

Small-cell lung cancer transformation approximately four years after surgery and adjuvant therapy for EGFR-mutant lung adenocarcinoma: a case report

Hong Wang, Boyu Qin, Jing Zhao, Hao Zhang, Lin Yang
article en

Abstract

Background Transformation of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) is a recognized mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and is associated with poor clinical outcomes. The optimal treatment strategy for transformed SCLC remains uncertain. Case presentation We report a case of EGFR exon 21 mutant lung adenocarcinoma in a 48-year-old woman who developed SCLC transformation approximately 4 years after surgery and postoperative adjuvant therapy. Clinical course and treatment Following the identification of SCLC, the patient received multiple treatment regimens, including platinum–etoposide chemotherapy, osimertinib, and local radiotherapy. A subsequent biopsy in 2019 again demonstrated small cell carcinoma. Peripheral blood molecular testing identified EGFR L858R, TP53 p.C242F, and RB1 c.607 + 1G > A-alterations. The patient died of respiratory failure in January 2020, approximately 6 years after the initial diagnosis and 20 months after the identification of SCLC transformation. Conclusion This case illustrates the clinical challenges of SCLC transformation in EGFR-mutant lung adenocarcinoma after a prolonged postoperative interval. The longitudinal treatment course and molecular findings provide additional clinical observations relevant to the management of transformed SCLC, although the contribution of individual treatments cannot be determined from a single case.

Frontiers in MedicineVol. 13
Chinese PLA General Hospital (CN)
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon